Avanir Pharmaceuticals announced that it has filed an IND application for its Phase 2 study of AVP-923 for the treatment of central neuropathic pain in patients with multiple sclerosis (MS).
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.